Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Completed × ARQ531 × Other hematologic neoplasm × Clear all

Phase

Status

Recruiting 3 Active not recruiting 3 Not yet recruiting 1 Completed 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1 Lymphoid 1

Conditions

Hematologic Neoplasms 1

Interventions

Cytarabine 409 Cyclophosphamide 400 fludarabine phosphate 244 Rituximab 221 Methotrexate 204 Etoposide 180 fludarabine 175 Filgrastim 173 Peripheral Blood Stem Cell Transplantation 147 Vincristine 142 Busulfan 141 Dexamethasone 131 Daunorubicin 130 Azacitidine 128 Mycophenolic Acid 120 Whole-Body Irradiation 117 Imatinib Mesylate 116 Cyclosporine 106 Tacrolimus 102 Radiotherapy 100 Melphalan 100 Idarubicin 94 Granulocyte Colony-Stimulating Factor 94 Doxorubicin 88 Mitoxantrone 87 Decitabine 87 Clofarabine 84 Antilymphocyte Serum 82 Lenalidomide 80 Prednisone 79

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06586671 2024-09-19

MK-1026-007

Merck Sharp & Dohme LLC

Phase 1 Completed

Other hematologic neoplasm

Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡